J&J Says CHMP Recommends Conversion Of Conditional Marketing Authorization For Sirturo (Bedaquiline) Into Standard Marketing Authorization
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson (JNJ) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the conversion of the conditional marketing authorization for Sirturo (bedaquiline) into a standard marketing authorization, according to Reuters.
April 29, 2024 | 2:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The CHMP's recommendation to convert Sirturo's marketing authorization from conditional to standard could enhance J&J's market position and potentially increase sales of the drug.
The conversion of Sirturo's marketing authorization status is a significant regulatory milestone that could lead to increased adoption and sales of the drug. This recommendation by the CHMP is likely to be viewed positively by investors and could lead to a short-term uptick in JNJ's stock price, reflecting the potential for increased revenue and market share in the pharmaceutical sector.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90